LivaNova (LIVN) revenue breakdown
By segment, Cardiopulmonary is the largest at 57% of fiscal 2025 revenue, growing 8% a year over 6 years.
By region, U.S. Pension Benefits is the largest at 53% of fiscal 2025 revenue, growing 5% a year over 9 years.
Revenue by segment
Fiscal years, as LivaNova reports them in its 10-K filings; fiscal 2025 total $1.4B.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiopulmonary | — | — | — | $505M | $447M | $483M | $514M | $604M | $684M | $785M | 57% |
| Neuromodulation | $351M | $375M | $423M | $425M | $354M | $456M | $477M | $520M | $554M | $593M | 43% |
| Cardiovascular | $612M | $636M | $682M | — | — | — | — | — | — | — | — |
| Advanced Circulatory Support | — | — | — | $32M | $42M | $55M | — | — | — | — | — |
Revenue by region
Fiscal years, as LivaNova reports them in its 10-K filings; fiscal 2025 total $1.4B.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. Pension Benefits | $481M | $495M | $553M | $546M | $469M | $571M | $572M | $635M | $695M | $740M | 53% |
| Rest of World | $279M | $307M | $325M | $315M | $272M | $263M | $271M | $304M | $338M | $379M | 27% |
| Europe | $205M | $210M | $229M | $223M | $193M | $202M | $179M | $215M | $220M | $269M | 19% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for LIVN.
Open LIVN in InvestinglyQuestions
Where does LivaNova make its money?
In fiscal 2025, by segment: Cardiopulmonary $785M, Neuromodulation $593M.
From LivaNova's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.